UK Access To Breast And Ovarian Cancer Test Is Goal Of Partnership
This article was originally published in The Gray Sheet
Executive Summary
The introduction and distribution of Myriad Genetics' BRACAnalysis test for hereditary breast and ovarian cancer risk in the UK would be facilitated through an intended partnership between the Salt Lake City, Utah-based firm and a UK partner by year-end.